Áö³ 5¿ù 14ÀÏ ‘Á¦84Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ’¿¡¼ Çмú»ó·ÇÇÀοë»ó ¼ö»ó
“Áö¼ÓÀûÀÎ ¿¬±¸ ÅëÇØ ³ÀÓ È¯Àڵ鿡°Ô ½ÇÁúÀû µµ¿ò ÁÙ °Í” ¼Ò°¨ ¹àÇô
[º¸°ÇŸÀÓÁî] ºÐ´ç¼¿ï´ëº´¿ø »êºÎÀΰú ±è½½±â ±³¼ö(»çÁø)´Â Áö³ 5¿ù 14ÀÏ °³ÃÖµÈ ‘Á¦ 84Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ¿¡’¼ ‘´ëÇÑ»ý½ÄÀÇÇÐȸ-¸ÓÅ© Çмú»ó’ °ú ‘´ëÇÑ»ý½ÄÀÇÇÐȸ-¸ÓÇÁ ÇÇÀοë»ó’À» ¼ö»óÇß´Ù.
Çмú»óÀº ºÐ´ç¼¿ï´ëº´¿ø »êºÎÀΰú ±è½½±â ±³¼ö¿Í Áöº´Ã¶ ±³¼ö°¡ °øµ¿ ±³½ÅÀúÀÚ·Î µîÀçµÈ ³ÀÓ ºÐ¾ß ¿¬±¸ ³í¹® ‘Correlation of oocyte number and serum anti-Mullerian hormone level measured either by Access or Elecsys in fresh IVF cycles(ü¿Ü¼öÁ¤½Ã¼ú¿¡¼ Çâ¹Ä·¯°ü È£¸£¸ó°ú ³ÀÚ ¼ö¿ÍÀÇ °ü°è)’ÀÇ ¿ì¼ö¼ºÀ» ÀÎÁ¤¹Þ¾Æ ¼ö»óÇß´Ù.
ÇÇÀοë»óÀÇ °æ¿ì Àڱ󻸷Áõ Ä¡·á¿¡ ´ëÇÑ ¸®ºä³í¹® ‘Management of endometriosis-related infertile patients: considerations and treatment options(Àڱ󻸷Áõ °ü·Ã ³ÀÓ È¯ÀÚ Ä¡·á¹ý)’ÀÌ ÀοëȽ¼ö°¡ °¡Àå ³ô¾Æ ±³½ÅÀúÀڷμ ¼ö»óÀÇ ¿µ¿¹¸¦ ¾È°Ô µÆ´Ù.
±è½½±â ±³¼ö´Â “¾ÕÀ¸·Îµµ ¿¬±¸¸¦ ÅëÇØ ³ÀÓ È¯Àڵ鿡°Ô ½ÇÁúÀû µµ¿òÀ» ÁÙ ¼ö ÀÖµµ·Ï ÃÖ¼±À» ´ÙÇÏ°Ú´Ù”°í ¹àÇû´Ù.